A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors
NCT ID: NCT05381909
Last Updated: 2026-02-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
157 participants
INTERVENTIONAL
2022-07-06
2025-07-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Investigational Study of BG-89894 Tablets in Participants With Advanced Solid Tumors
NCT06568614
Study of BC3195 Monotherapy in Patients With Advanced Solid Tumors
NCT05957471
A Phase I Study of BMS-690514 in Patients With Advanced or Metastatic Solid Tumors
NCT00329004
Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB2916 Injection in Patients With Advanced Malignant Tumors
NCT05213767
A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors
NCT02442414
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Phase 1a: Dose Escalation Part E
Participants will receive increasing dose levels of BGB-24714 in combination with chemoradiation in Chinese participants
Carboplatin
administered intravenously
BGB-24714
administered orally
Paclitaxel
administered intravenously
Phase 1b: Dose Expansion
BGB 24714 will be administered in combination with paclitaxel or docetaxel in participants with selected solid tumors.
Docetaxel
administered intravenously
BGB-24714
administered orally
Paclitaxel
administered intravenously
Phase 1a: Dose Escalation Part C
Participants will receive increasing dose levels of BGB-24714 in combination with chemoradiation
Carboplatin
administered intravenously
BGB-24714
administered orally
Paclitaxel
administered intravenously
Phase 1a: Dose Escalation Part D
Participants will receive increasing dose levels of BGB-24714 in combination with chemoradiation
Carboplatin
administered intravenously
BGB-24714
administered orally
Paclitaxel
administered intravenously
Phase 1a: Dose Escalation Part A-CN
Participants will receive escalating doses of BGB-24714 as monotherapy in Chinese participants
BGB-24714
administered orally
Phase 1a: Dose Escalation Part A
Participants will receive escalating doses of BGB-24714 as monotherapy
BGB-24714
administered orally
Phase 1a: Dose Escalation Part B
Participants will receive increasing dose levels of BGB-24714 in combination with paclitaxel
BGB-24714
administered orally
Paclitaxel
administered intravenously
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Carboplatin
administered intravenously
Docetaxel
administered intravenously
BGB-24714
administered orally
Paclitaxel
administered intravenously
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Part D: Participant with locally advanced, histologically confirmed inoperable esophageal squamous cell carcinoma (ESCC) suitable for definitive CRT
Phase 1b (Dose Expansion): Participants with histologically or cytologically confirmed solid tumors of selected types previously treated with standard therapy.
3. Participants must be able to provide formalin-fixed paraffin embedded (FFPE) tumor tissue sample.
4. Phase 1a Part A, A-CN, B and Phase 1b: ≥ 1 measurable lesion per Response evaluation criteria in solid tumors (RECIST) v1.1
5. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1
Exclusion Criteria
2. Any malignancy ≤ 3 years before the first dose of study drug(s) except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated with curative intent
3. Any condition that required systemic treatment with either corticosteroids or other immunosuppressive medication ≤ 14 days before the first dose of study drug(s).
4. Clinically significant infection requiring systemic therapy ≤ 14 days before the first dose of study drug(s).
5. Prior exposure to agents with second mitochondria-derived activator of caspases (SMAC) mimetics, or other Inhibitors of apoptosis proteins (IAPs) antagonists.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
BeiGene
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Banner Md Anderson Cancer Center
Gilbert, Arizona, United States
Florida Cancer Specialist (Scri) Sarasota
Sarasota, Florida, United States
Scri Florida Cancer Specialists North
St. Petersburg, Florida, United States
Scri Florida Cancer Specialist East
West Palm Beach, Florida, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States
Hackensack University Medical Center
Hackensack, New Jersey, United States
Upmc Hillman Cancer Center(Univ of Pittsburgh)
Pittsburgh, Pennsylvania, United States
Sanford Cancer Center
Sioux Falls, South Dakota, United States
Avera Cancer Institute
Sioux Falls, South Dakota, United States
Tennessee Oncology, Pllc Nashville
Nashville, Tennessee, United States
Mary Crowley Cancer Research
Dallas, Texas, United States
University of Texas Southwestern Medical Center
Dallas, Texas, United States
The University of Texas Md Anderson Cancer Center (Department Gi Medical Oncology)
Houston, Texas, United States
Intermountain Healthcare
Salt Lake City, Utah, United States
Next Virginia
Fairfax, Virginia, United States
University of Washington
Seattle, Washington, United States
Northern Beaches Hospital
Frenchs Forest, New South Wales, Australia
Icon Cancer Centre South Brisbane
South Brisbane, Queensland, Australia
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
Austin Health
Heidelberg, Victoria, Australia
Peter Maccallum Cancer Centre
Melbourne, Victoria, Australia
Sunshine Hospital
St Albans, Victoria, Australia
Chongqing Cancer Hospital
Chongqing, Chongqing Municipality, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Hunan Cancer Hospital
Changsha, Hunan, China
Shandong Provincial Hospital
Jinan, Shandong, China
Shandong Cancer Hospital
Jinan, Shandong, China
Auckland City Hospital
Auckland, , New Zealand
National Cancer Center (Korea)
IlsandongGu GoyangSi, Gyeonggi-do, South Korea
Gachon University Gil Medical Center
NamdongGu, Incheon Gwang'yeogsi, South Korea
Samsung Medical Center
GangnamGu, Seoul Teugbyeolsi, South Korea
Severance Hospital Yonsei University Health System
SeodaemunGu, Seoul Teugbyeolsi, South Korea
Asan Medical Center
SongpaGu, Seoul Teugbyeolsi, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CTR20232532
Identifier Type: OTHER
Identifier Source: secondary_id
BGB-24714-101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.